Lymphocyte transformation and production of lymphocyte-derived chemotactic factor in response to herpes simplex virus antigen were studied in 15 patients with initial genital herpes and 10 controls. The patients underwent frequent genital examinations, viral cultures, and weekly immunological studies for a period of 11 weeks. The production of lymphocyte-derived chemotactic factor was maximal in week 1 of the disease and declined to control levels by week 6. In contrast, lymphocyte transformation was lowest in week 1, reached a maximum by week 4, and declined to control levels by week 11 . Production of lymphocytederived chemotactic factor in week 1 was significantly lower in nine patients who developed signs or symptoms of systemic herpes infection than in six who had localized disease. In addition, a marked but transient decline in the production of this lymphokine was observed in patients at the time of clinical recurrence. Virusspecific lymphocyte transformation correlated inversely with the duration of genital pain and lesions and did not correlate with the presence of systemic signs or symptoms. These findings indicate that during initial genital herpes infection the dynamics of lymphocyte transformation and those of lymphocyte-derived chemotactic factor production are different, and that the generation of this lymphokine is an early component of the cellular immune response in this disease. Furthermore, adequate produce of lymphocyte-derived chemotactic factor may be important in restricting herpes simplex virus to the genital area and preventing disease recurrence.
The host response to herpes simplex virus (HSV) infection includes humoral and cellular immunity; however, the relationship between specific immunity and the severity of clinical disease is incompletely understood. Recurrent infections develop in the presence of high titers of virus-specific neutralizing antibody, and severe herpetic infections occur in individuals with impaired cell-mediated immunity (15) . For these reasons, investigators have examined various aspects of cellular immunity in patients with HSV infections (17, 20, 21, 24, 25) ; however, most previous studies have focused on recurrent disease, and there is little information available regarding cell-mediated immunity in initial HSV infections. Recently, we demonstrated that the proliferative response of lymphocytes from patients with initial genital HSV infection reached a maximum during the 4th week of the disease and that the magnitude of the response was inversely correlated with the duration of viral shedding and the persistence of symptoms (4) . The present study was initiated to evaluate the development and evolution of lymphokine synthesis during initial genital HSV infection and to examine the relationship of this response to that of lymphocyte transformation and the clinical manifestations of disease. For this purpose, we performed weekly clinical examinations, viral cultures, and measurements of lymphocyte-derived chemotactic factor (LDCF) production and lymphocyte transformation in 15 patients. Our studies show that maximal LDCF production occurs in the 1st week of infection in advance of lymphocyte transformation and that adequate production of this mediator may be important in controlling the severity of initial herpetic infection and the development of recurrent disease.
(This study was presented in part at the An- (2) .
Titers of complement-fixing antibody to HSV and neutralizing antibody to HSV type 1 (HSV-1) and HSV-2 were measured in serum specimens taken at the initial and 4th-week visits, using previously described methods (5, 14, 30) .
HSV antigen preparation. HSV antigen was prepared as previously described (4) . Briefly LDCF was produced by culturing 1.5 ml of the mononuclear cell suspensions in serum-free media with 25 pl of the HSV-1 or HSV-2 antigens or phytohemagglutinin (PHA; 10 jg/ml; Burroughs Wellcome Co., Research Triangle Park, N.C.) for 48 h at 370C in 5% CO2 in air. Earlier studies have shown these conditions to be optimal for LDCF production (1). The cell suspensions were then centrifuged at 300 x g for 10 min, and the cell-free culture supernatants were frozen at -700C until they were tested for chemotactic activity. To measure spontaneous or unstimulated LDCF synthesis, cells were cultured for 48 h without HSV or PHA. Twenty-five-microliter portions of PHA or inactivated HSV antigens were added to these control tubes immediately before centrifugation.
Chemotactic assay. Monocyte chemotaxis was measured in modified Boyden chambers, using 5-gum polycarbonate filters (Nuclepore Corp., Pleasanton, Calif.) (26) . Normal human mononuclear cells at 7.5
x 105 myeloperoxidase-positive cells monocytess) per ml in Gey balanced salt solution were used as responder cells. These cell suspensions were placed in the upper compartment of Boyden chambers. The culture supernatants to be tested for chemotactic activity were diluted to 33% (vol/vol) with a mixture of Gey balanced salt solution and gelatin Veronal buffer and placed in the lower compartment of the chemotaxis chamber. In all experiments, 10% (vol/vol) bacterial chemotactic factor (BCTX) (29) and phosphatebuffered saline (PBS), pH 7.2, were used as positive and negative controls, respectively. These concentrations of LDCF and BCTX produced approximately half-maximal chemotactic responses (Table 1) and hence were selected to maximize the sensitivity of the chemotactic assay. Cells in the chemotaxis chambers were incubated for 90 min at 370C. The filters were then removed and stained with Meyer hematoxylin and Wright stains, and leukocyte migration was quan- The mean duration of local symptoms (pain, itching, discharge, and dysuria) was 14.4 ± 2.3 days. The duration ofviral shedding from genital lesions (defined as the time from the onset of lesions until the last positive viral culture) averaged 9.5 ± 1.2 days (range, 3 to 18). The mean time until re-epithelialization oflesions was complete was 21.0 ± 1.9 days. These data are similar to those presented in our previous study on the clinical course of initial genital HSV infection (4).
Nine of the 15 patients had fever, headache, malaise, myalgias, or photophobia in the 1st week of disease. The mean duration of these systemic signs and symptoms was 7.0 ± 2.1 days. The mean duration of local symptoms was longer (itching, 13.9 ± 0.9 day; pain, 17.1 ± 1.2 days) in the patients with systemic signs or symptoms than in those with localized disease (8.4 ± 3.6 and 10.7 ± 1.2 days, respectively; P < 0.05).
Recurrent infection developed in 12 patients. The mean time between initial and recurrent infection was 49 ± 7 days (range, 29 to 81), and the average period for which patients were studied was 186 + 22 days (range, 30 to 307).
Production of LDCF in response to inactivated HSV antigen and PHA. The production of LDCF by patients' lymphocytes stimulated with homologous HSV antigens varied during the course of infection. The greatest production occurred in the 1st week of disease (29.0 ± 7.5) and declined thereafter (24.0 + 7.2, 21.0 + 2 through 6, respectively; week 1 versus week 6, P < 0.05). In contrast, LDCF production by cells from controls was significantly lower and did not vary over the course of the investigation (Fig. 1) . Production of LDCF in response to heterologous HSV antigen (i.e., HSV-1 when HSV-2 was the patient's isolate) fluctuated without a significant trend. Furthermore, LDCF generation in response to PHA did not differ between patients and controls, and the production of this lymphokine by PHA-stimulated patients' lymphocytes did not vary over the course of the investigation.
Production of LDCF and clinical disease. The production of LDCF in response to homologous HSV antigen was significantly lower in week 1 of disease in the nine patients who experienced systemic signs or symptoms than in the six whose disease was localized to the genitalia (15.3 ± 4.8 and 49.6 ± 14.0, respectively; P < 0.05; Fig. 2 ). In weeks 2 through 6, HSVstimulated lymphokine production was similar in the two groups of patients. In contrast, no significant correlations were observed between the magnitude of the LDCF response to HSV antigen at week 1 ). In those patients whose disease re-8.5 at week 3, 44.6 ± 13.5 at week 4, and 24.4 ± [,LDCF production was significantly lower 6.1 at week 6. By week 11, the response of > the week of recurrence than in the weeks patients' lymphocytes had declined to 7.7 + 3.2 lately preceding or following, although (Fig. 4) . Although our intention was to study aal LDCF production was similar in pa-only patients with initial HSV infections, 12 of who developed recurrent infection and in the 15 patients we followed developed recurwho did not (34.6 ± 3.5 and 54.9 ± 14.3, rences, and lymphocyte transformation genertively; not significant) (Fig. 3) .
ally increased in the week after the onset of a ationship between lymphocyte trans-recurrence. However, the time of peak lymphoLtion response and clinical disease. cyte transformation, i.e., week 4, was unaffected aean transformation response of patients' by these recurrent infections since they all occurred between weeks 4 and 11. In contrast to the temporal rise and fall in transformation of patient lymphocytes, the proliferation of control lymphocytes to HSV was low and did not fluctuate over the course of the study. Furthermore, the transformation of patients' lymphocytes to PHA, ConA, and PWM did not vary with the course of disease and did not differ from the response of control lymphocytes to these mitogens.
There were inverse correlations between the magnitude of lymphocyte transformation to 2 Table 3 ). The 1. Temporal course ofHSV-stimulatedLDCF maximal proliferative response to HSV antigen Stion inpatients with initial genital HSVinfec-was 45.9 + 11.8 in the eight patients who had -0*) and in controls (v---4@). The value for pain for more than 15 days and 83.2 + 14.9 in ts at week 1 is significantly different from that the seven who had pain for less than 15 days (P k 6 and from that for controls at week 1, both < 0.05). Similarly, the maximal response to HSV 05.
antigen was significantly lower in the four pa-VOL. 30, 1980 on September Production of LDCF by HSV-stimulated lymphocytes from patients with recurrent infection. Weeks -1, 0, and +1 are the week before recurrence, the week ofrecurrence, and the week after recurrence, respectively. The values at weeks -I and +1 are both significantly different from those at week 0 at P < 0.05 and <0.001, respectively. tients in whom the healing oflesions was delayed (-25 days) than in those whose healing was more rapid (mean stimulation index of 27.9 10.0 versus 76.3 ± 16.3; P < 0.05). In contrast, the duration of viral shedding from genital lesions did not correlate with lymphocyte transformation. Although this finding differs from that of our previous study (4) , the discrepancy may in part be explained by the fact that we studied fewer patients in the present study. DISCUSSION The most significant findings of the present study are that (i) virus-specific lymphokine, LDCF, production in initial genital HSV infection was highest during the 1st week of disease and declined to control levels by week ( -) and in controls (v-4). with this virus. In addition, the finding that a transient deficiency in herpes-specific LDCF production occurred at the time of recurrence suggests that this mediator may play a role in preventing the development of recurrent HSV infection. Alternatively, recurrent disease may cause a transient decline in LDCF production because the cells which produce this mediator are temporarily sequestered at the site of the genital lesions. The present study also shows that the transformation of lymphocytes from patients with initial HSV infection was lowest in the 1st week of disease, increased to a peak at week 4, and returned to control levels by week 11. The magnitude of the transformation response to HSV antigens was found to correlate inversely with the duration of local symptoms and the persistence of lesions. That is, patients who experienced pain for more than 15 days or had lesions that persisted for more than 25 days had significantly lower lymphocyte transformation responses to HSV antigen than did patients whose pain and lesions resolved in less time. These findings verify our previous observations (4) .
Lymphokine production and lymphocyte transformation in HSV infection have been examined in earlier investigations. However, these studies have focused primarily on recurrent disease. Shillitoe and co-workers (24) found that lymphocyte transformation to HSV-1 was higher during the 1st week of infection in patients with recurrent herpes labialis than in seropositive controls. They also found that production of migration inhibition factor (MIF) was lowest in the 1st week after a recurrence, which led them to speculate that a transient decline in MIF synthesis may have permitted the reactivation of the latent viral infection. In a later study, the same investigators reported that both MIF production and lymphocyte proliferation in response to HSV antigen were functions of T cells and that lymphocytes from patients with primary herpes labialis manifested a peak proliferative response within 2 weeks after symptom onset (25) . O'Reilly and co-workers (17) found that HSV-specific transformation could be regularly detected in lymphocyte cultures from patients with recurrent herpes labialis and herpes progenitalis, irrespective of the clinical stage of their infection. In contrast, they found transient declines in the HSV-stimulated production of leukocyte MIF (LMIF) and interferon at the time of and immediately before HSV recurrence. The synthesis of these mediators was found to increase significantly during convalescence. Rasmussen and co-workers, in a study of patients with recurrent HSV infection, found that interferon production was maximal between weeks 2 and 6 after disease onset and that patients whose lymphocytes produced high titers of interferon had less frequent recurrences (19) . Furthermore, these authors observed that lymphocyte transformation was unrelated to disease activity and appeared to reflect prior immune status. Rosenberg et al. (22) reported that peripheral lymphocytes from individuals who had antibodies to HSV produced LDCF in response to HSV antigen, whereas cells from antibody-negative individuals did not. Of interest, we found that two of our controls were CF antibody positive to HSV, although their lymphocytes were unresponsive to this antigen as determined by LDCF production and lymphocyte transformation. This observation, although not consistent with some earlier studies, such as that of Rosenberg et al. (22) , is in keeping with our previous work (4) in which we showed that lymphocyte responsiveness correlated more closely with disease activity than with serological status. That is, we found that patients may remain seropositive to HSV and have lymphocytes which fail to respond in vitro. It is evident from the above studies that our understanding of the development of cellular immunity during the course of HSV infection is incomplete. It is interesting to note, however, that Shillitoe et al. found a transient decrease in MIF synthesis and that O'Reilly et al. found a similar abnormality in leukocyte MIF and interferon production coincident with disease recurrence. These observations are comparable to our finding that LDCF production was significantly lower in patients with recurrent HSV infection at the time that the recurrence first developed.
A number of lines of evidence suggest that normal monocyte-macrophage accumulation and function may be important in host defense against herpetic infections. These include the present study and the work of Shillitoe et al., which indicate that there are abnormalities in the synthesis of lymphokines which affect monocyte-macrophages in HSV infections (24) . In addition, studies by Zisman et al. (32) and McGeorge and Morahan (11) have shown that the dissemination of HSV in mice was enhanced and the mortality increased when the animals had been pretreated with macrophage-inhibiting agents such as silica, trypan blue, dextran sulfate, and antimacrophage serum. Other studies (8, 9, 13) 
